Royalty Pharma plc Operating Cash Flow
Royalty Pharma plc (RPRX) reported Operating Cash Flow of $1.45 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Royalty Pharma plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $728.46M, a 100.14% increase year-over-year.
- Royalty Pharma plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $718.23M, a 20.49% increase year-over-year.
- Royalty Pharma plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $827.15M, a 11.40% increase year-over-year.
- Royalty Pharma plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $702.62M, a 0.14% decline year-over-year.
- Royalty Pharma plc net cash provided by (used in) operating activities for fiscal 2025 was $2.49B, a 10.08% decline from fiscal 2024.
- Royalty Pharma plc net cash provided by (used in) operating activities for fiscal 2024 was $2.77B, a 7.32% decline from fiscal 2023.
- Royalty Pharma plc net cash provided by (used in) operating activities for fiscal 2023 was $2.99B, a 39.36% increase from fiscal 2022.
- Royalty Pharma plc net cash provided by (used in) operating activities for fiscal 2022 was $2.14B, a 6.27% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $728.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.45B 10-Q · filed 2026-08-05 | $2.27B derived: sum of 3 quarters · filed 2026-08-05 | $2.98B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $718.23M 10-Q · filed 2026-05-06 | $1.55B derived: sum of 2 quarters · filed 2026-05-06 | $2.25B derived: sum of 3 quarters · filed 2026-05-06 | $2.61B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $827.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.53B derived: sum of 2 quarters · filed 2026-02-11 | $1.89B derived: sum of 3 quarters · filed 2026-08-05 | $2.49B 10-K · filed 2026-02-11 |
| 2025-09-30 | $702.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.07B derived: sum of 2 quarters · filed 2026-08-05 | $1.66B 10-Q · filed 2025-11-05 | $2.41B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $363.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $960.06M 10-Q · filed 2026-08-05 | $1.70B derived: sum of 3 quarters · filed 2026-08-05 | $2.41B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $596.08M 10-Q · filed 2026-05-06 | $1.34B derived: sum of 2 quarters · filed 2026-05-06 | $2.04B derived: sum of 3 quarters · filed 2026-05-06 | $2.70B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $742.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.45B derived: sum of 2 quarters · filed 2026-02-11 | $2.10B derived: sum of 3 quarters · filed 2026-02-11 | $2.77B 10-K · filed 2026-02-11 |
| 2024-09-30 | $703.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.36B derived: sum of 2 quarters · filed 2025-11-05 | $2.03B 10-Q · filed 2025-11-05 | $2.80B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $658.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.32B 10-Q · filed 2025-08-06 | $2.10B derived: sum of 3 quarters · filed 2026-02-11 | $2.67B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $664.64M 10-Q · filed 2025-05-08 | $1.44B derived: sum of 2 quarters · filed 2026-02-11 | $2.01B derived: sum of 3 quarters · filed 2026-02-11 | $2.62B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $772.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.35B derived: sum of 2 quarters · filed 2026-02-11 | $1.95B derived: sum of 3 quarters · filed 2026-02-11 | $2.99B 10-K · filed 2026-02-11 |
| 2023-09-30 | $573.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.18B derived: sum of 2 quarters · filed 2024-11-06 | $2.22B 10-Q · filed 2024-11-06 | $2.79B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $607.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.64B 10-Q · filed 2024-08-08 | $2.21B derived: sum of 3 quarters · filed 2025-02-12 | $2.75B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $1.03B 10-Q · filed 2024-05-09 | $1.60B derived: sum of 2 quarters · filed 2025-02-12 | $2.14B derived: sum of 3 quarters · filed 2025-02-12 | $2.72B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $569.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.11B derived: sum of 2 quarters · filed 2025-02-12 | $1.68B derived: sum of 3 quarters · filed 2025-02-12 | $2.14B 10-K · filed 2025-02-12 |
| 2022-09-30 | $538.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.11B derived: sum of 2 quarters · filed 2023-11-08 | $1.57B 10-Q · filed 2023-11-08 | $2.06B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $574.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.04B 10-Q · filed 2023-08-08 | $1.53B derived: sum of 3 quarters · filed 2024-02-15 | $1.99B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $460.27M 10-Q · filed 2023-05-09 | $950.23M derived: sum of 2 quarters · filed 2024-02-15 | $1.42B derived: sum of 3 quarters · filed 2024-02-15 | $1.95B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $489.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $959.72M derived: sum of 2 quarters · filed 2024-02-15 | $1.49B derived: sum of 3 quarters · filed 2024-02-15 | $2.02B 10-K · filed 2024-02-15 |
| 2021-09-30 | $469.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.00B derived: sum of 2 quarters · filed 2022-11-08 | $1.53B 10-Q · filed 2022-11-08 | $2.09B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $531.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.06B 10-Q · filed 2022-08-04 | $1.62B derived: sum of 3 quarters · filed 2023-02-15 | $2.13B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $526.10M 10-Q · filed 2022-05-05 | $1.09B derived: sum of 2 quarters · filed 2023-02-15 | $1.60B derived: sum of 3 quarters · filed 2023-02-15 | $2.09B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $565.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.07B derived: sum of 2 quarters · filed 2023-02-15 | $1.56B derived: sum of 3 quarters · filed 2023-02-15 | $2.03B 10-K · filed 2023-02-15 |
| 2020-09-30 | $508.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $997.85M derived: sum of 2 quarters · filed 2021-11-10 | $1.47B 10-Q · filed 2021-11-10 | $1.95B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $489.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $960.11M 10-Q · filed 2021-08-11 | $1.44B derived: sum of 3 quarters · filed 2022-02-15 | $1.86B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $471.10M 10-Q · filed 2021-05-11 | $949.53M derived: sum of 2 quarters · filed 2022-02-15 | $1.37B derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $478.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $897.46M derived: sum of 2 quarters · filed 2022-02-15 | $1.67B 10-K · filed 2022-02-15 | |
| 2019-09-30 | $419.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.19B 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $769.78M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $1.62B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |